Botulinum Toxin-A Compared with Cetirizine in the Treatment of Allergic Rhinitis

Phase 2

Conditions: Allergic rhinitis.
Vasomotor and allergic rhinitis

Registration Number: IRCT201208261579N3

Lead Sponsor: Vice Chancellor for Research, Isfahan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 50

Inclusion Criteria

1- Adult patients with allergic rhinitis according to the Allergic Rhinitis and its Impact on Asthma criteria,
2- Having at least three symptoms of sneezing, nasal congestion, and rhinorrhea.

Exclusion criteria:
1- History of nasal anatomic abnormality,
2- Persistent asthma,
3- Long term use of systemic corticosteroids,
4- Malignancy, tuberculosis, diabetes mellitus, or other chronic systemic disease,
5- History of rhinoplasty,
6- Pregnant women,
7- Being on local corticosteroids at the time of enrollment.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sneezing. Timepoint: Baseline and every two weeks for two months. Method of measurement: Allergic Rhinitis and its Impact on Asthma Questionnaire.;Rhinorrhea. Timepoint: Baseline and every two weeks for two months. Method of measurement: Allergic Rhinitis and its Impact on Asthma Questionnaire.;Nasal congestion. Timepoint: Baseline and every two weeks for two months. Method of measurement: Allergic Rhinitis and its Impact on Asthma Questionnaire.;Nasal itching. Timepoint: Baseline and every two weeks for two months. Method of measurement: Allergic Rhinitis and its Impact on Asthma Questionnaire.;Eye irritation. Timepoint: Baseline and every two weeks for two months. Method of measurement: Allergic Rhinitis and its Impact on Asthma Questionnaire.

Secondary Outcome Measures

Name	Time	Method
Quality of life. Timepoint: Before and two months after the study. Method of measurement: Rhinasthma Questionnaire.;Nasal dryness. Timepoint: Every two weeks for two months. Method of measurement: Interview with patient.;Epistaxis. Timepoint: Every two weeks for two months. Method of measurement: Interview with patient.;Sleepiness. Timepoint: Every two weeks for two months. Method of measurement: Interview with patient.;Blurred vision. Timepoint: Every two weeks for two months. Method of measurement: Interview with patient.